Do calcium channel blockers increase the risk of cancer?
Do calcium channel blockers increase the risk of cancer?
复制标题
DOI：
10.1016/0895-7061(96)00186-0
复制
发表时间：
1996-07-01
影响因子：
3.2
通讯作者：
Havlik, RJ
中科院分区：
文献类型：
--
作者：
Pahor, M;Guralnik, JM;Havlik, RJ
钙通道阻滞剂可以阻断触发细胞分化和凋亡的钙信号，这是肿瘤生长调节的重要机制。为了确定钙通道阻滞剂的使用是否与癌症风险增加有关，从1988年至1992年对750名年龄大于或等于71岁、基线时无癌症病史的高血压患者进行了随访。患者使用β受体阻滞剂、血管紧张素转换酶抑制剂或钙通道阻滞剂（维拉帕米、硝苯地平和地尔硫卓;主要是短效品种）。与β受体阻滞剂相比（n = 424，28起事件），在校正年龄、性别、种族、吸烟、体重指数和与癌症无关的住院次数后，血管紧张素转换酶抑制剂（95%置信区间）（n = 124，6起事件）和钙通道阻滞剂（n = 202，27起事件）分别为0.73（0.30至1.78）和2.02（1.16至3.54）。这些发现表明，钙通道阻滞剂治疗可能会增加癌症的风险。在使用现代钙通道阻滞剂的患者中需要新的数据，这些药物的吸收更缓慢。本报告应鼓励进一步研究易患癌症和正在接受钙通道阻滞剂的老年患者的癌症结局。
Calcium channel blockers can block calcium signals that trigger cell differentiation and apoptosis, which are important mechanisms of cancer growth regulation. To ascertain whether calcium channel blocker use was associated with an increased risk of cancer, 750 hypertensive persons age greater than or equal to 71 years, with no history of cancer at baseline, were followed from 1988 through 1992. The patients were using either beta-blockers, angiotensin converting enzyme inhibitors or calcium channel blockers (verapamil, nifedipine, and diltiazem; mainly of the short-acting variety). Compared to beta-blockers (n = 424, 28 events), after adjusting for age, gender, race, smoking, body mass index, and number of hospital admissions not related with cancer, the relative risks of cancer (95% confidence interval) for angiotensin converting enzyme inhibitors (n = 124, 6 events) and calcium channel blockers (n = 202, 27 events) were 0.73 (0.30 to 1.78) and 2.02 (1.16 to 3.54), respectively. These findings indicate that calcium channel blocker therapy might increase the risk of cancer. New data are needed in patients using modern calcium channel blocker agents with more gradual absorption. This report should encourage further study of cancer outcomes in elderly patients who are vulnerable to cancer and who are receiving calcium channel blockers.